Exenatide


GLP-1 receptor agonist (exendin-4)

A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

Abstract

Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph